|Bid||0.00 x 3100|
|Ask||0.00 x 2200|
|Day's range||12.07 - 12.53|
|52-week range||12.07 - 18.86|
|Beta (5Y monthly)||1.42|
|PE ratio (TTM)||N/A|
|Earnings date||08 Nov 2021|
|Forward dividend & yield||0.44 (3.57%)|
|Ex-dividend date||22 Nov 2021|
|1y target est||20.38|
Viatris Inc. (NASDAQ: VTRS) today announced that the United States Court of Appeals for the Federal Circuit affirmed the June 2020 decision by the U.S. District Court for the Northern District of West Virginia invalidating Biogen's Tecfidera® patent, U.S. Patent No. 8,399,514, for lack of written description. The company launched the first therapeutically equivalent substitutable generic to Tecfidera in August 2020.
If you're a fan of stable healthcare companies that have the potential to pay you ever-rising dividends until the cows come home, Viatris (NASDAQ: VTRS) might well become a dream stock. The single most persuasive argument against it being too late to buy Viatris is that the company is just getting started. After all, its life as an independent entity started a mere year ago with the merger of Pfizer's generic drugs business, Upjohn, and Mylan.
Here's why they think Bristol Myers Squibb (NYSE: BMY), Novartis (NYSE: NVS), and Viatris (NASDAQ: VTRS) are too cheap to ignore. Prosper Junior Bakiny (Bristol Myers Squibb): Investors are sometimes wary of undervalued companies.